In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from ...
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-831. Data from the Group Health Atrial ...
Minneapolis, MN - New research shows that alendronate is not cost-effective in treating postmenopausal women with low bone mass. The findings suggest that drug therapy may not be advisable for women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback